KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Outstanding (Weighted Average) (2018 - 2025)

Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $134.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 6.07% year-over-year to $134.4 million; the TTM value through Dec 2025 reached $134.4 million, down 6.07%, while the annual FY2025 figure was $134.4 million, 6.07% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $134.4 million in Q4 2025 per AUPH's latest filing, up from $131.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $144.0 million in Q1 2024 to a low of $127.4 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $138.3 million, with a median of $141.8 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 14.08% in 2021, then decreased 7.86% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $129.4 million in 2021, then rose by 9.7% to $141.9 million in 2022, then grew by 0.93% to $143.2 million in 2023, then fell by 0.12% to $143.1 million in 2024, then decreased by 6.07% to $134.4 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Shares Outstanding (Weighted Average) are $134.4 million (Q4 2025), $131.8 million (Q3 2025), and $134.9 million (Q2 2025).